Neurofilament light chain (NfL) and glial fibrillary acid protein (GFAP) as biomarkers disease activity and therapeutic response in multiple sclerosis treated with ocrelizumab
Neurologie pro praxi · 20.07.2026 · 27 (3) · 218-221
DOI: 10.36290/neu.2026.033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurologie pro praxi, erschienen am 20.07.2026. Verfasst von Pavel Štourač. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
Roztrouen sklerza je chronick autoimunitn onemocnn s velmi variabilnm interindividulnm klinickm prbhem a odpovd na lbu. V souasnosti je snaha najt biomarkery, kter by odrely dva zkladn aspekty patogeneze, jednak zntlivou aktivitu a neurodegeneraci. Nyn mme k dispozici dva biomarkery, lehk etzce neurofilament a gliln fibrilrn acidick protein, jejich srov hladiny odrej zntlivou aktivitu a neurodegeneraci v rmci patologickho procesu. Stanovenm jejich hladin bude v budoucnu mon sledovat innost liv, a jak je uvedeno v tomto sdlen zejmna ocrelizumabu u roztrouen sklerzy, a vas modifikovat lbu na principu personalizovan medicny.
Zitieren
APA
Štourač, P. (2026). Neurofilament light chain (NfL) and glial fibrillary acid protein (GFAP) as biomarkers disease activity and therapeutic response in multiple sclerosis treated with ocrelizumab. Neurologie pro praxi, 27(3), 218-221. https://doi.org/10.36290/neu.2026.033
Vancouver
Štourač P. Neurofilament light chain (NfL) and glial fibrillary acid protein (GFAP) as biomarkers disease activity and therapeutic response in multiple sclerosis treated with ocrelizumab. Neurologie pro praxi. 2026;27(3):218-221. doi:10.36290/neu.2026.033
BibTeX
@article{toura2026,
author = {Štourač, Pavel},
title = {Neurofilament light chain (NfL) and glial fibrillary acid protein (GFAP) as biomarkers disease activity and therapeutic response in multiple sclerosis treated with ocrelizumab},
journal = {Neurologie pro praxi},
year = {2026},
volume = {27},
number = {3},
pages = {218--221},
doi = {10.36290/neu.2026.033}
}
EUVIMED